Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Parasitol Res ; 123(1): 64, 2023 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-38117414

RESUMO

This study aimed to investigate the effect of rosuvastatin treatment on anxiety-related behavior and short- and long-term memory impairment in mice infected with acute RH and BRI strains of Toxoplasma gondii. Balb/C mice were infected intraperitoneally and after 2 h, oral treatment with rosuvastatin (40 mg/kg/day) was initiated for 4 days. Behaviors related to anxiety and locomotion were evaluated in the open field (OF), and short- and long-term memory through the novel object recognition test (NOR). At the end of the experiments, peritoneal fluid, brain, liver, and lung were collected for T. gondii DNA quantification and histopathological analysis. Infection with BRI strain reduced the dwell time and central locomotion in the OF (p < 0.05), indicating anxiogenic type behavior, while treatment with rosuvastatin reversed this response (p < 0.05). RH strain infection did not alter any behavior in the OF (p > 0.05) and both strains impaired short- and long-term memory (NOR test), but with no significant treatment effect (p > 0.05). The BRI strain was shown to be more damaging in relation to anxiogenic type behavior when compared to the RH strain (p < 0.05), whereas rosuvastatin reduced this damaging effect in BRI. The treatment reduced the parasite load in the peritoneal lavage, liver, and lung of animals infected with both acute strains; however, it significantly (p < 0.05) attenuated the inflammatory process only in BRI-infected and treated animals, showing that non-archetypal genotypes are more damaging in rodents. This suggests that rosuvastatin may be a drug with great therapeutic potential against T. gondii mainly to reduce damage from virulent strains.


Assuntos
Toxoplasma , Animais , Camundongos , Rosuvastatina Cálcica/uso terapêutico , Brasil , Inflamação/tratamento farmacológico , Camundongos Endogâmicos BALB C
2.
PLoS One ; 16(4): e0250079, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33857221

RESUMO

The aim of this study was to investigate the effect of rosuvastatin treatment on memory impairment, and anxiogenic-like effects in mice chronically infected with Toxoplasma gondii. For this, Balb/c mice were infected orally with chronic ME-49 strain of Toxoplasma gondii. Oral treatment with rosuvastatin (40mg/kg/day) started on the 51st day post-infection and was performed daily for 21 days. After completion of treatment, anxiety-like effects and locomotion were investigated in the open field (OF) test, whereas novel object recognition (NOR) test was used for evaluation of short- and long-term memory. At the end of the experiments, the brain was collected for Toxoplasma gondii DNA quantification and histopathological analysis. Infection with ME-49 strain decreased the time spent in the center of OF, indicating an anxiogenic effect, without affecting total and peripheral locomotion. Rosuvastatin treatment inhibited the change in the center time. Besides, pharmacological treatment increased total and central locomotion in both non-infected and infected animals. Infection also impaired both short- and long-term memory in the NOR test, and these effects were reverted by rosuvastatin treatment. In addition to effects in behavioral changes, rosuvastatin also reduced parasite load in the brain and attenuated signs of brain inflammation such as perivascular cuffs, inflammatory cell infiltration and tissue damage. These findings indicate for the first time the efficacy of rosuvastatin in treatment of memory impairment and anxiogenic effect evoked by infection with Toxoplasma gondii. These effects might be mediated by reduced cyst load, which in turn decrease inflammation and damage in the brain.


Assuntos
Ansiedade/tratamento farmacológico , Transtornos da Memória/tratamento farmacológico , Memória/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Rosuvastatina Cálcica/uso terapêutico , Toxoplasmose/complicações , Animais , Ansiolíticos/farmacologia , Ansiolíticos/uso terapêutico , Ansiedade/etiologia , Feminino , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Transtornos da Memória/etiologia , Camundongos , Rosuvastatina Cálcica/farmacologia , Toxoplasma
3.
Diagn Microbiol Infect Dis ; 43(1): 85-6, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12052633

RESUMO

We developed a new screening test for C. dubliniensis based on its inability to grow on Sabouraud dextrose broth with 6.5% NaCl. A total of 266 clinical yeast isolates and 3 reference strains were tested, including 250 C. albicans and 19 C. dubliniensis strains. All C. albicans isolates tested exhibited significant growth on hypertonic Sabouraud broth up to 96 h, while, all C. dubliniensis isolates did not exhibit any visually detectable growth during the same period.


Assuntos
Candida/classificação , Candida/efeitos dos fármacos , Candidíase/diagnóstico , Candidíase/microbiologia , Meios de Cultura/química , Meios de Cultura/farmacologia , Técnicas de Tipagem Micológica/métodos , Candida/crescimento & desenvolvimento , Candida/isolamento & purificação , Candida albicans/classificação , Candida albicans/efeitos dos fármacos , Candida albicans/crescimento & desenvolvimento , Candida albicans/isolamento & purificação , Divisão Celular/efeitos dos fármacos , Glucose , Humanos , Soluções Hipertônicas , Concentração Osmolar , Sensibilidade e Especificidade , Cloreto de Sódio , Especificidade da Espécie , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA